FDA's First Step In Xenazine Review: Work Around Clinical Evidence Guidance

Shepherding the orphan Huntington’s chorea drug Xenazine through a three-year review, top-level FDA reviewers invoked the concept of "confirmatory evidence" to circumvent the agency’s preference for two randomized clinical trials to support new drug approval.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet